1. A 72-year-old man with Parkinson's disease, type 2 diabetes (25 years), and chronic heart failure (EF 35%) is admitted with dizziness and two syncopal episodes. His current medications include carbidopa-levodopa, metoprolol succinate 50 mg daily, lisinopril 10 mg daily, and furosemide 20 mg daily. His supine BP is 156/94 mmHg and standing BP drops to 78/46 mmHg within 60 seconds. Autonomic testing confirms neurogenic orthostatic hypotension. His neurologist wants to add midodrine 5 mg TID. Which of the following most accurately identifies the pharmacological concerns specific to initiating midodrine in this particular patient?

• A) The pharmacological concerns with midodrine in this patient are: (1) Supine hypertension risk compounded by existing hypertension -- this patient already has supine BP 156/94 mmHg (suggestive of preserved supine vascular tone from the neurogenic orthostatic failure being position-specific rather than total autonomic failure); adding an alpha-1 agonist will further elevate supine BP, risking hypertensive emergency, acute LV afterload increase (in the setting of EF 35% -- the failing LV is particularly sensitive to afterload increases), and acute cerebrovascular events; meticulous dosing timing counseling is essential (last dose 4+ hours before bedtime) and home supine BP monitoring is required; (2) Drug interaction with metoprolol -- beta-1 blockade by metoprolol reduces the compensatory heart rate increase that normally partially offsets orthostatic BP drop; midodrine and metoprolol in combination may worsen orthostatic hypotension if the baroreceptor reflex-mediated tachycardia (normally a compensatory response to orthostasis) is blunted by the beta-1 blocker; conversely, midodrine's reflex bradycardia (from alpha-1-mediated BP rise) may be compounded by metoprolol's beta-1 blockade; (3) CHF and preload -- midodrine's alpha-1 venoconstriction increases venous return (reducing venous capacitance), which may worsen left-sided filling pressure (PCWP) in a patient with EF 35% and impaired ventricular compliance; acute decompensated heart failure is a potential risk; monitor for worsening dyspnea, edema, or pulmonary congestion; (4) Diabetes -- diabetic autonomic neuropathy may reduce the patient's ability to mount compensatory baroreceptor responses, making orthostasis more severe and midodrine potentially more effective per dose; adjust doses starting low; (5) Urinary retention risk in elderly male (alpha-1 contraction of urethral sphincter).
• B) The primary pharmacological concern with midodrine in this patient is its interaction with lisinopril -- midodrine activates alpha-1 receptors on the afferent arteriole, increasing glomerular hydrostatic pressure; lisinopril reduces angiotensin II-mediated efferent arteriolar constriction; the opposing effects on glomerular hemodynamics produce acute GFR fluctuations that may cause AKI; the combination of midodrine plus ACE inhibitor is therefore contraindicated in patients with pre-existing renal insufficiency.
• C) Midodrine is absolutely contraindicated in patients with Parkinson's disease because carbidopa blocks peripheral DOPA decarboxylase, the enzyme responsible for converting midodrine to its active metabolite desglymidodrine; without DOPA decarboxylase activity, midodrine cannot be activated and would be ineffective; additionally, peripheral carbidopa inhibition of DOPA decarboxylase could also block midodrine's active metabolite from being further metabolized, leading to dangerous accumulation.
• D) The key pharmacological concerns: (1) Supine hypertension risk exacerbated by pre-existing hypertension (supine BP 156/94) and by the reduced cardiac reserve from EF 35% (increased afterload from alpha-1 vasoconstriction may cause acute decompensated heart failure); (2) Potential worsening of CHF from venoconstriction increasing preload in an already volume-burdened heart; (3) Interaction with furosemide: midodrine's alpha-1-mediated venoconstriction counteracts furosemide's venodilatory effect (furosemide reduces preload via prostaglandin-mediated venodilation), requiring higher furosemide doses; (4) Male patient urinary retention risk from alpha-1 urethral sphincter contraction; management plan: start midodrine at 2.5 mg TID, dose before periods of peak activity, last dose 4+ hours before lying down, head-of-bed elevation, BP monitoring both supine and standing, cardiology co-management for CHF monitoring.

2. A 45-year-old woman with moderate persistent asthma on fluticasone-salmeterol 250/50 twice daily presents with a 5-day history of worsening wheeze and dyspnea following a viral upper respiratory infection. On auscultation, bilateral diffuse wheeze is present. SpO2 is 91% on room air. Peak expiratory flow is 42% of her personal best. She is started on nebulized albuterol 2.5 mg every 20 minutes x3 doses and IV methylprednisolone. After three albuterol doses, SpO2 improves to 97% and wheeze is reduced. Which of the following most accurately explains the receptor-level mechanism of the acute response to albuterol and the role of methylprednisolone in the management of this exacerbation?

• A) Albuterol mechanism in acute asthma: beta-2 receptor activation (Gs-adenylyl cyclase-cAMP-PKA) on bronchial smooth muscle cells; PKA phosphorylates MLCK (reducing its activity, less myosin phosphorylation, reduced contractile tone -> airway smooth muscle relaxation and bronchodilation); PKA also activates large-conductance BKCa channels (K+ efflux -> membrane hyperpolarization -> reduced voltage-gated Ca2+ channel opening -> less Ca2+ influx -> less Ca2+-calmodulin-MLCK activation); the combined MLCK inhibition and hyperpolarization relaxes the bronchospasm within 5-10 minutes; dosing frequency in acute asthma: 2.5 mg via nebulizer every 20 minutes x3 ("back-to-back" or "triple dose" approach) -- the rationale: in severe acute bronchospasm, airway wall edema and mucus obstruction reduce drug delivery to the receptor; the intense bronchoconstriction also reduces inhaled drug access to distal airways; frequent repeat dosing maintains sustained receptor occupancy and allows drug delivery to initially obstructed airways as partial bronchodilation opens access; SABA beta-2 receptors in severe asthma are partially downregulated (GRK-mediated from prior LABA exposure and from the inflammatory cytokine milieu); higher effective doses overcome partial receptor downregulation. Methylprednisolone mechanism: glucocorticoid receptor (GR) nuclear translocation -> GRE (glucocorticoid response element)-mediated gene regulation; anti-inflammatory mechanisms: (1) Transrepression of NF-kB: blocks NF-kB-dependent transcription of IL-4, IL-5, IL-13, TNF-alpha, and eotaxin -- the key eosinophilic and TH2 cytokines driving asthma airway inflammation; (2) Transrepression of AP-1: reduces MMP expression and reduces inflammatory cell recruitment; (3) GRE-dependent transcription: increases anti-inflammatory proteins (lipocortin-1/annexin A1 -- inhibits phospholipase A2 and prostaglandin/leukotriene synthesis; MAPK phosphatase-1 -- inhibits p38 MAPK inflammatory signaling); (4) Reduces vascular permeability (reducing mucosal edema); (5) Upregulates beta-2 receptor gene expression (preventing SABA tachyphylaxis); onset: 4-6 hours for full anti-inflammatory effect; immediate bronchodilation from corticosteroids is minimal; methylprednisolone prevents the secondary worsening phase (late-phase inflammatory response) that would otherwise occur 4-8 hours after the acute episode resolves.
• B) Albuterol acts on beta-1 receptors in the bronchioles to increase cAMP and relax airway smooth muscle -- the "beta-2" terminology for bronchodilators is a historical classification error; all adrenergic bronchodilators act on beta-1 receptors because the bronchial vasculature (not the smooth muscle) is the target; methylprednisolone reduces airway inflammation by blocking histamine receptors in the airway mucosa; the combination of beta-1 bronchodilation and histamine blockade is the mechanism of acute asthma exacerbation management.
• C) Albuterol produces bronchodilation through beta-2-Gs-cAMP-PKA-MLCK inhibition in bronchial smooth muscle; the repeated dosing protocol (every 20 minutes x3) maintains sustained high receptor occupancy to overcome partial downregulation from prior LABA exposure; methylprednisolone provides anti-inflammatory benefit (NF-kB and AP-1 transrepression reducing eosinophilic inflammation) with onset 4-6 hours -- insufficient for acute bronchodilation but essential for preventing the late-phase inflammatory response and secondary worsening; methylprednisolone also upregulates beta-2 receptor expression (GRE-mediated ADRB2 transcription), enhancing albuterol sensitivity over the following 12-24 hours; this synergistic relationship between ICS/systemic corticosteroids and beta-2 agonist sensitivity is a key pharmacological principle in asthma management.
• D) Albuterol produces bronchodilation in acute asthma by activating beta-2 receptors on bronchial mast cells, inhibiting their degranulation and reducing histamine and leukotriene release; the reduction in histamine-mediated bronchospasm is the primary mechanism of albuterol's bronchodilator effect; direct smooth muscle relaxation is a minor secondary mechanism; methylprednisolone works by increasing endogenous epinephrine secretion from the adrenal medulla -- glucocorticoid receptors in the adrenal medulla stimulate PNMT (the enzyme converting NE to epinephrine), increasing circulating epinephrine which produces direct bronchodilation via beta-2 receptors; this is the primary mechanism of action of systemic corticosteroids in acute asthma.

3. A 52-year-old man with a 15-year history of hypertension managed with clonidine 0.3 mg twice daily is admitted for elective hip replacement. He had his last clonidine dose at 6:00 AM. Surgery begins at 2:00 PM, is uneventful, and ends at 5:00 PM. He is kept NPO overnight for nausea. By 11:00 PM (17 hours after his last clonidine dose), he develops severe headache, diaphoresis, and his BP is 226/138 mmHg (baseline 136/84 mmHg). HR is 114 bpm. Which of the following most accurately identifies the mechanism of this presentation and the pharmacological management approach?

• A) This presentation is clonidine rebound hypertension from abrupt discontinuation in the perioperative NPO period -- the mechanism: clonidine's plasma half-life is approximately 12-16 hours; after 17 hours without a dose, plasma levels have fallen by more than 50%; chronic clonidine therapy had downregulated presynaptic alpha-2 autoreceptors (GRK-mediated, from sustained agonist exposure); with falling clonidine plasma levels, the downregulated autoreceptors cannot reassert adequate inhibitory control over NE release; a sympathetic NE surge occurs, producing marked alpha-1-mediated hypertension (226/138 mmHg) and beta-1-mediated tachycardia (HR 114); diaphoresis and headache are from the catecholamine excess; management options: (1) Resume clonidine: if the patient can take oral medications, restart the home dose; transdermal clonidine patch (Catapres-TTS [transdermal therapeutic system]) can be applied and will achieve therapeutic plasma levels within 2-3 days -- provides a bridge during the NPO period but is too slow for acute management of the current crisis; (2) IV labetalol: the preferred acute parenteral agent -- combined alpha-1 blocking effect counteracts the vasoconstriction; beta-1 blocking effect controls tachycardia; avoids the danger of pure beta-blockers in the setting of an ongoing alpha-1-mediated NE surge (pure beta-1 blockade could worsen hypertension by removing tachycardic offset of vasoconstriction -- same principle as pheochromocytoma management); (3) IV phentolamine (alpha-1 and alpha-2 blocker) is an alternative for the hypertensive component; (4) If patient can resume oral intake, oral clonidine is the most direct treatment; prevention: clonidine should be explicitly listed as a "do not hold perioperatively" medication or converted to a transdermal patch before any procedure with anticipated NPO period.
• B) This presentation is hypertensive emergency from unrecognized pheochromocytoma triggered by surgical catecholamine release -- the tumor was suppressed by clonidine's central sympatholysis (clonidine is commonly used to suppress pheochromocytoma catecholamine secretion); withdrawal of clonidine postoperatively allowed the tumor to release its stored catecholamines; management requires IV phentolamine (alpha-1 blocker) followed by beta-blockade; plasma metanephrines should be sent immediately and adrenalectomy planned urgently.
• C) Clonidine rebound hypertension is not the correct diagnosis -- clonidine's half-life is 12-16 hours and 17 hours after the last dose, plasma levels are only 50% reduced; this is not pharmacologically sufficient to produce rebound hypertension; the correct diagnosis is postoperative pain-mediated hypertension (surgical stress produces catecholamine release from the adrenal medulla); management is parenteral opioid analgesia to reduce surgical pain, with blood pressure normalization expected after adequate pain control; no specific clonidine-related management is needed.
• D) Clonidine rebound hypertension from perioperative NPO-related missed doses is the diagnosis; mechanism: alpha-2 autoreceptor downregulation during chronic therapy -> NE surge on dose discontinuation -> alpha-1 hypertension + beta-1 tachycardia; management: (1) IV labetalol (first-line: combined alpha+beta blockade addresses both hypertension and tachycardia without the risk of unopposed alpha-1 vasoconstriction from pure beta-blockers); (2) Restart clonidine via available route (oral if tolerated; crushed tablet via NG tube; transdermal patch for bridge while NPO continues -- note patch takes 2-3 days to reach steady state); (3) Never use pure beta-blockers alone in the acute NE surge -- removing the beta-1 chronotropic offset of alpha-1 vasoconstriction can worsen the hypertension; prevention in future: list clonidine as "do not interrupt perioperatively" or convert to transdermal formulation before planned procedures with NPO period.

4. A 68-year-old woman is in the surgical ICU following Whipple procedure (pancreaticoduodenectomy). She is intubated and mechanically ventilated on postoperative day 1. She is agitated and fighting the ventilator. The anesthesiologist proposes starting dexmedetomidine infusion for sedation. Her current vitals: BP 142/88 mmHg, HR 72 bpm (sinus rhythm). Her PMH includes hypertension, type 2 diabetes, and stage 2 CKD. Which of the following most accurately identifies the specific pharmacological monitoring considerations and potential adverse effects of initiating dexmedetomidine in this patient?

• A) The key pharmacological monitoring considerations for dexmedetomidine in this post-surgical ICU patient: (1) Bradycardia risk: dexmedetomidine's alpha-2-mediated central sympatholysis (LC suppression) reduces adrenergic tone to the SA node and AV node, reducing heart rate; at baseline HR 72 bpm, significant bradycardia may occur (HR below 50 bpm) requiring intervention; monitoring: continuous ECG; be prepared to treat with atropine IV (0.5-1 mg) or temporary pacing for severe bradycardia; avoid rapid loading bolus (administer over at least 10 minutes or omit loading dose entirely); (2) Transient hypertension from loading: IV dexmedetomidine loading infusion activates peripheral vascular alpha-2B receptors (on vascular smooth muscle, Gq-coupled -- paradoxical vasoconstriction in the peripheral vasculature before the central sympatholytic effect dominates); this peripheral alpha-2B vasoconstriction produces a transient hypertensive response during and shortly after loading; in a patient with BP 142/88 mmHg who is not yet on adequate antihypertensive therapy postoperatively, this transient BP spike may be clinically significant; management: administer the loading dose slowly (over 10-20 minutes) or skip the loading dose and start the maintenance infusion at a lower dose; (3) Hypotension from central sympatholysis: as the loading-dose hypertension subsides and central alpha-2A sympatholytic effect dominates, BP can fall; monitor closely for hypotension (particularly in volume-depleted postoperative patients); (4) Renal excretion: dexmedetomidine and its metabolites are primarily renally excreted; in CKD stage 2 (eGFR 60-89), no dose adjustment is required at this level of renal insufficiency; (5) Respiratory monitoring: dexmedetomidine produces less respiratory depression than GABAergic agents but is not free of respiratory effects at high doses; it may facilitate ventilator weaning (patients remain arousable and can cooperate with weaning trials) -- an important advantage in this extubation candidate; (6) Duration: if infusion exceeds 24 hours, monitor for tolerance and withdrawal effects on discontinuation.
• B) Dexmedetomidine should not be used in post-surgical patients because its alpha-2 agonist mechanism stimulates GH secretion from the pituitary (alpha-2 receptors on somatotrophs release GH); elevated postoperative GH in a diabetic patient worsens hyperglycemia and impairs wound healing; the correct sedative for intubated ICU patients with diabetes is propofol (which suppresses pituitary GH via GABA-A mechanism); dexmedetomidine's CYP3A4 metabolism in the liver is also significantly impaired after Whipple procedure (which removes the pancreatic head and common bile duct), dramatically reducing its clearance and causing dangerous accumulation.
• C) Dexmedetomidine monitoring in this patient should focus primarily on its significant drug interaction with metformin -- dexmedetomidine's alpha-2-mediated reduction in pancreatic beta-cell cAMP reduces insulin secretion, causing hyperglycemia that triggers compensatory increased metformin use; in a patient with CKD stage 2, the combination of reduced renal clearance of both drugs causes significant accumulation of both dexmedetomidine and metformin, risking lactic acidosis; withhold metformin and monitor lactate closely during dexmedetomidine infusion.
• D) Dexmedetomidine initiation monitoring in this surgical ICU patient: (1) Bradycardia monitoring (continuous ECG -- HR 72 bpm at baseline, risk of symptomatic bradycardia from alpha-2 SA/AV node sympatholysis; have atropine ready; avoid bolus loading); (2) Biphasic BP response: initial transient hypertension from peripheral alpha-2B vasoconstriction during loading (clinically relevant in this already hypertensive patient -- skip or slow the loading dose), followed by central alpha-2A-mediated hypotension from sympatholysis as drug distributes centrally (particularly risky in volume-depleted postoperative patients; monitor MAP closely and have vasopressors available); (3) CKD stage 2: no dose adjustment required at this level; monitor for accumulation if CKD worsens postoperatively; (4) Respiratory: less depression than propofol or midazolam; cooperative sedation enables daily sedation interruption trials and ventilator weaning without full awakening; (5) Glucose monitoring: alpha-2-mediated suppression of pancreatic beta-cell insulin secretion (presynaptic alpha-2 inhibitory autoreceptors on beta cells reduce insulin release) may worsen glycemic control in this diabetic patient; check glucose every 2-4 hours during infusion.

5. A 34-year-old woman with severe persistent asthma is seen in the emergency department for an acute exacerbation. She uses albuterol MDI about 8 times per day and has been using it more frequently over the past 2 weeks. She uses fluticasone-salmeterol 500/50 twice daily but frequently forgets the evening dose. She denies any recent illness or change in environment. Her PEF is 38% of personal best. Which of the following most accurately identifies the pharmacological mechanisms contributing to her reduced response to albuterol over the prior 2 weeks and explains the likely contribution of salmeterol to this phenomenon?

• A) Her reduced albuterol response reflects receptor-level tachyphylaxis from excessive SABA use: using albuterol 8 times/day provides near-continuous beta-2 receptor agonist exposure; GRK2 phosphorylates beta-2 receptors on bronchial smooth muscle cells at multiple intracellular domain serine/threonine residues; phosphorylated receptors recruit beta-arrestin-2, which sterically uncouples the receptor from Gs-protein coupling and reduces cAMP generation per receptor activation; with both albuterol (8 doses/day direct agonism) and salmeterol (twice-daily LABA -- providing continuous near-maximal beta-2 occupancy) contributing to beta-2 receptor agonist exposure, the degree of GRK-mediated downregulation is additive; surface beta-2 receptor density has fallen due to receptor internalization and reduced recycling; each albuterol dose now activates fewer functional surface receptors and generates less bronchodilation per dose; she is in a pharmacological cycle: reduced beta-2 receptor availability -> less bronchodilation per dose -> more frequent albuterol use -> greater receptor downregulation -> even less bronchodilation; the salmeterol component is particularly relevant: LABAs in asthma monotherapy (without adequate ICS) produce continuous beta-2 agonism that drives GRK-mediated receptor downregulation in the absence of corticosteroid-mediated upregulation; her frequent missed evening fluticasone doses may have reduced the ICS coverage that normally prevents salmeterol-induced receptor downregulation; management: intensify systemic corticosteroids (course of oral prednisolone to restore beta-2 receptor density via GRE-mediated ADRB2 upregulation), treat the acute exacerbation with aggressive SABA plus ipratropium, and address adherence to ICS dosing.
• B) Her reduced response to albuterol is caused by drug tolerance at the airway smooth muscle level -- albuterol is converted by CYP2D6 in airway smooth muscle cells to an active metabolite (S-albuterol) that is an inverse beta-2 agonist; with 8 doses/day, the S-albuterol accumulation competitively antagonizes the R-albuterol bronchodilator effect; this is why levalbuterol (pure R-albuterol without the S-enantiomer) should be substituted; salmeterol contributes by activating alpha-2 receptors in the bronchial mucosa, producing bronchoconstriction at the high tissue concentrations achieved with twice-daily dosing; stopping salmeterol would immediately improve albuterol response.
• C) The reduced albuterol response results from beta-2 receptor downregulation from combined SABA overuse and suboptimal ICS coverage allowing LABA-driven downregulation: albuterol 8 times/day plus salmeterol twice-daily provides near-continuous beta-2 agonist exposure driving GRK2-mediated receptor phosphorylation, beta-arrestin recruitment, internalization, and surface receptor density reduction; corticosteroids (via GRE-mediated ADRB2 transcription) upregulate beta-2 receptors and counteract agonist-induced downregulation -- but missed fluticasone doses reduce this protective upregulation; the net balance: ongoing LABA/SABA receptor downregulation versus insufficient corticosteroid upregulation results in reduced beta-2 receptor density and reduced albuterol responsiveness; ICS adherence is pharmacologically essential not only as an anti-inflammatory but as a beta-2 receptor density maintainer; management: systemic corticosteroid burst to acutely upregulate beta-2 receptors + treat exacerbation + adherence counseling.
• D) The reduced albuterol response is due entirely to the natural progression of her severe persistent asthma -- as asthma becomes more severe, airway remodeling (smooth muscle hypertrophy, subepithelial fibrosis) physically reduces the proportion of bronchial smooth muscle that can respond to beta-2 receptor stimulation; the increased albuterol use reflects her attempts to overcome this irreversible remodeling; salmeterol is unrelated to the reduced SABA response; the appropriate management is referral for bronchial thermoplasty (ablation of excess smooth muscle by radiofrequency energy) rather than pharmacological adjustments.

6. A 77-year-old woman is prescribed oxybutynin 5 mg TID for overactive bladder. Three months later, her daughter reports that she has become more forgetful, is having difficulty with word-finding, and her MMSE score has dropped from 27/30 to 22/30. The urologist considers switching to mirabegron. Which of the following most accurately explains the pharmacological basis for oxybutynin-induced cognitive impairment and why mirabegron would not be expected to cause this adverse effect?

• A) Oxybutynin's cognitive toxicity mechanism: oxybutynin is a non-selective antimuscarinic drug that blocks M1, M2, and M3 receptors; crucially, oxybutynin's high lipophilicity allows significant CNS penetration and M1 receptor blockade in the cerebral cortex and hippocampus; central M1 receptor blockade impairs cholinergic neurotransmission that is critical for memory consolidation, attention, and cognitive processing; the cholinergic hypothesis of Alzheimer's disease recognizes the central importance of M1 receptor signaling in memory and attention; oxybutynin's central M1 blockade produces an anticholinergic cognitive impairment that may mimic, exacerbate, or unmask underlying neurodegenerative disease in elderly patients; in elderly patients, the blood-brain barrier is more permeable and brain cholinergic reserve is reduced (age-related decline in basal forebrain cholinergic neurons), making them disproportionately vulnerable to anticholinergic cognitive toxicity; oxybutynin has a particularly high central anticholinergic burden among OAB medications (anticholinergic cognitive burden score = 3, the maximum); more bladder-selective antimuscarinic alternatives (darifenacin -- M3-selective; trospium -- quaternary ammonium, does not cross BBB; solifenacin) have lower central anticholinergic burden; mirabegron mechanism -- why no cognitive toxicity: mirabegron activates beta-3 adrenergic receptors on the detrusor smooth muscle (Gs-cAMP-PKA-MLCK inhibition) without any muscarinic receptor antagonism; it does not cross the BBB in significant quantities (less lipophilic than oxybutynin); it has no central cholinergic activity; therefore it cannot produce anticholinergic cognitive effects; epidemiological studies show no association between mirabegron use and cognitive decline or dementia; mirabegron is the preferred OAB medication in elderly patients with cognitive vulnerability.
• B) Oxybutynin causes cognitive impairment through its inhibition of acetylcholinesterase (AChE) -- by blocking AChE, oxybutynin prevents the degradation of ACh in the synapse; the resulting excess ACh causes muscarinic receptor desensitization throughout the CNS, leading to paradoxical muscarinic hypofunction; mirabegron avoids this because it activates beta-3 receptors and stimulates AChE activity, restoring normal ACh degradation.
• C) Oxybutynin's cognitive toxicity reflects its M1 CNS receptor blockade in the hippocampus and cortex (high lipophilicity allowing BBB penetration + non-selective M1/M2/M3 antagonism with particularly important M1 cognitive circuit disruption); elderly patients are disproportionately vulnerable from reduced cholinergic reserve and increased BBB permeability; oxybutynin has the highest anticholinergic burden score (3) among OAB agents; mirabegron (beta-3 agonist on detrusor, Gs-cAMP mechanism, no muscarinic receptor activity, limited CNS penetration) produces therapeutic OAB benefit without any cholinergic mechanism and is not associated with cognitive decline -- making it the pharmacological rational choice for this patient; transitioning from oxybutynin to mirabegron would be expected to reverse the anticholinergic cognitive impairment gradually over weeks as oxybutynin is cleared.
• D) Oxybutynin causes cognitive decline through its interference with beta-amyloid clearance from the brain -- M2 receptor activation normally promotes lymphatic drainage of beta-amyloid from the CSF via the glymphatic system; oxybutynin's M2 blockade impairs this clearance, allowing beta-amyloid accumulation and accelerating Alzheimer's pathology; mirabegron activates beta-3 receptors that enhance glymphatic clearance of beta-amyloid, making it not only cognitively safe but potentially neuroprotective.